As More Smoke Pot, Are Their Jobs at Risk?
5:00 PM CST.
Read article
- AHA: Too Much of This in the Blood Could Predict Unhealthy Aging
- Mindfulness Might Ease Menopause Symptoms
- Many Addiction Centers Lack Anti-Opioid Meds: Study
- IVF Won’t Cause Birth Complications: Study
JOURNAL UPDATE
Canadian Syncope Risk Score IDs ED Monitoring Time Postsyncope
7:00 PM CST. Half of arrhythmias identified within 2 hours in low-risk patients, within 6 hours in medium-, high-risk…- CDC: Slight Hike in Prevalence of Gastroschisis Since 2006-2010
- Medical Cannabis Decisions Being Made by Users, Not Doctors
- Heberden’s Nodes in Fingers Tied to Knee Osteoarthritis
MONTHLY JOURNAL SUMMARY
December 2018 Briefing - Pharmacy
January 02, 2019. The Monthly Journal Summary is a single article covering the most important journal articles published in the previous 30 days.
FEATURED ARTICLES
Rucaparib Maintenance Therapy Improves PFS in Platinum-sensitive Ovarian Cancer - The ARIEL3 Trial
Robert L. Coleman, MD.
Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of…
Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
Ted Lain, MD.
Clinical trial investigator Dr. Ted Lain comments on the results of the OPAL study, a Phase 2b clinical trial which evaluated the efficacy of a novel topical gel formulation of the antibiotic minocycline (BPX-01) in reducing the number of inflammatory lesions in patients with moderate-to-severe inflammatory,…
Characterization of patients with ovarian carcinoma who respond to the PARP inhibitor rucaparib
Elizabeth M. Swisher, MD.
Dr. Elizabeth M. Swisher comments on the implications of new data from the ARIEL2 trial, an ongoing Phase 2 trial of the novel PARP inhibitor rucaparib in relapsed, high-grade serous or endometrioid ovarian cancer. The new results offer an important insight into the genetic mechanisms behind tumor sensitivity…
MEDICAL FOCUS
Alzheimer’s disease
By Tamer M. Fouad, M.D.Alzheimer’s disease (AD) is the most common cause of dementia in Western countries.
DISCUSSION
RE: Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
By MrRobinGreat articles. learnt a lot from it.
ANNOUNCEMENTS
Sunday Times - Doctors Lounge Voted top 10 best ‘Ask an expert’ website
Times Online / The Sunday Times voted Doctors Lounge as 3rd best ‘Ask an expert’ website.
